Lowenstein Sandler has advised Relmada Therapeutics. Holland & Hart has advised the book-running managers. Relmada Therapeutics, a clinical-stage biotechnology company listed on Nasdaq under the symbol...
Relmada Therapeutics Announces $100 Million Underwritten Offering
PerkinElmer’s Acquisition of Project Farma
Lowenstein Sandler represented PerkinElmer in the transaction. PerkinElmer, a global leader in analytical solutions and specialized services for (bio)pharma, applied and food markets, announced the acquisition...
Crown Laboratories’ $924 Million Merger with Revance Therapeutics
Skadden is advising Revance Therapeutics, while Kirkland & Ellis and Lowenstein Sandler are advising Crown Laboratories on the deal. Crown Laboratories, Inc., a privately held, global...
Hildred Capital’s $750 Million Continuation Fund
Lowenstein Sandler represented Hildred Capital in the transaction. Hildred Capital raised $750 million for its continuation fund to extend its ownership of two of its portfolio companies, Hyland’s...
Tava Health’s $20 Million Series B Funding Round
Lowenstein Sandler represented Catalyst Investors on the transaction. Tava Health, Inc., a provider of virtual mental health and telehealth services to therapists and employee assistance programs,...
First Wave BioPharma’s Acquisition of ImmunogenX
Lowenstein represented First Wave BioPharma, Inc. in the transaction. First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic...
Timber Pharmaceuticals’ Chapter 11 and Asset Sale to Leo Pharma
Lowenstein Sandler represented Timber Pharmaceuticals, Inc. in the transaction. Timber Pharmaceuticals, Inc. (NYSE: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for...
Big Health’s Acquisition of Limbix
Lowenstein Sandler represented Big Health in the transaction. Big Health, the leading provider of non-drug digital treatments for mental health, announced the acquisition of Limbix, creators...
Tonix Pharmaceuticals’ $25 Million Acquisition of FDA-Approved Products from Upsher-Smith Laboratories
Lowenstein represented Tonix Pharmaceuticals Holding Corp. in the transaction. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a clinical-stage biopharmaceutical company, announced its $25 million acquisition of two...
Traub Capital’s Investment in Sabatino Tartufi
Lowenstein Sandler represented Traub Capital Partners in the transaction. Traub Capital Partners, a strategic private equity firm specializing in building value in consumer companies using its...
Coya Therapeutics’ $15.25 Million Initial Public Offering
Lowenstein Sandler represented Coya Therapeutics in the transaction. Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory...
LTS Lohmann Therapy Systems’ Acquisition of Tapemark
Lowenstein Sandler represented LTS Lohmann Therapy Systems, Corp. in the transaction. LTS Lohmann Therapy Systems, Corp. (“LTS”) executed its acquisition of Tapemark Inc. (“Tapemark”) located in...